CanSino Biologics Inc. (HKG:6185)

Market Cap	13.81B -8.5%
Revenue (ttm)	1.47B +29.4%
Net Income	34.77M
EPS	0.14
Shares Out	247.04M
PE Ratio	190.00
Forward PE	21.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,987,214
Open	26.90
Previous Close	27.16
Day's Range	26.20 - 27.00
52-Week Range	19.22 - 46.78
Beta	1.17
Analysts	Strong Buy
Price Target	42.86 (+60.52%)
Earnings Date	Oct 27, 2026

About CanSino Biologics

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 1,175
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6185

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 4 analysts, the average rating for 6185 stock is "Strong Buy." The 12-month stock price target is $42.86, which is an increase of 60.52% from the latest price.

Price Target

$42.86

(60.52% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error